SI-BONE (SIBN) Competitors

LeMaitre Vascular (NASDAQ:LMAT) and SI-BONE (NASDAQ:SIBN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.

Do analysts rate LMAT or SIBN?

LeMaitre Vascular presently has a consensus target price of $98.14, indicating a potential upside of 8.76%. SI-BONE has a consensus target price of $24.40, indicating a potential upside of 78.36%. Given SI-BONE's stronger consensus rating and higher possible upside, analysts plainly believe SI-BONE is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63
SI-BONE	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor LMAT or SIBN?

LeMaitre Vascular received 343 more outperform votes than SI-BONE when rated by MarketBeat users. Likewise, 70.45% of users gave LeMaitre Vascular an outperform vote while only 68.80% of users gave SI-BONE an outperform vote.

Company	Underperform	Outperform
LeMaitre Vascular	Outperform Votes 515 70.45%	Underperform Votes 216 29.55%
SI-BONE	Outperform Votes 172 68.80%	Underperform Votes 78 31.20%

Do institutionals and insiders believe in LMAT or SIBN?

84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 98.1% of SI-BONE shares are owned by institutional investors. 10.8% of LeMaitre Vascular shares are owned by company insiders. Comparatively, 3.9% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, LMAT or SIBN?

LeMaitre Vascular has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Does the media favor LMAT or SIBN?

In the previous week, LeMaitre Vascular had 9 more articles in the media than SI-BONE. MarketBeat recorded 15 mentions for LeMaitre Vascular and 6 mentions for SI-BONE. SI-BONE's average media sentiment score of 1.52 beat LeMaitre Vascular's score of 0.97 indicating that SI-BONE is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	4 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SI-BONE	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is LMAT or SIBN more profitable?

LeMaitre Vascular has a net margin of 19.40% compared to SI-BONE's net margin of -23.82%. LeMaitre Vascular's return on equity of 13.15% beat SI-BONE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	19.40%	13.15%	11.47%
SI-BONE	-23.82%	-22.51%	-16.53%

Which has better earnings and valuation, LMAT or SIBN?

LeMaitre Vascular has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$219.86M	9.27	$30.10M	$1.94	46.52
SI-BONE	$167.18M	3.47	-$43.34M	-$0.76	-18.00

Summary

LeMaitre Vascular beats SI-BONE on 13 of the 19 factors compared between the two stocks.